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Abstract: To produce the wide range of blood and immune cell types, haematopoietic stem cells can 
“choose” directly from the entire spectrum of blood cell fate-options. Affiliation to a single cell 
lineage can occur at the level of the haematopoietic stem cell and these cells are therefore a mixture 
of some pluripotent cells and many cells with lineage signatures. Even so, haematopoietic stem cells 
and their progeny that have chosen a particular fate can still “change their mind” and adopt a 
different developmental pathway. Many of the leukaemias arise in haematopoietic stem cells with 
the bulk of the often partially differentiated leukaemia cells belonging to just one cell type. We argue 
that the reason for this is that an oncogenic insult to the genome “hard wires” leukaemia stem cells, 
either through development or at some stage, to one cell lineage. Unlike normal haematopoietic 
stem cells, oncogene-transformed leukaemia stem cells and their progeny are unable to adopt an 
alternative pathway. 
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1. Introduction 
The mechanisms by which haematopoietic stem cells (HSCs) “choose” to develop towards a 
particular specialised cell are still unclear. The process of decision-making comprises of a number of 
steps, including the generation of a number of possible options, the selection of one option from the 
range and whether there is irrevocable closure of other options or do they remain latent/clandestine. 
There is also the matter of how a cell “remembers” and passes on a fate to its progeny. To move 
towards a model of these aspects to stem cell behaviour requires a better understanding of various 
factors including stochastic and ordered gene expression, the overall architecture of the network of 
the control components and the influence of external factors [1]. 
The lineage-affiliation and differentiation status of cells equates to both the repertoire of 
transcription factors that is available and chromatin structure governance of the accessibility of cis-
regulatory elements. Individual transcription factors that drive the gene expression for cells to 
develop along a pathway can additionally close down other developmental options. These processes 
can therefore occur simultaneously (reviewed in [2]). For example, PU.1 activates myeloid-specific 
genes and represses erythroid-, innate lymphoid cell (ILC)-, and T-cell-affiliated genes in a 
concentration dependent manner. PU.1 therefore enforces myeloid and B-cell fates and directs 
progenitors away from erythroid, ILC and T-cell fates [3]. High levels of the erythroid Kruppel-like 
factor EKLF expression promote erythropoiesis whilst suppressing megakaryopoiesis, in part by 
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repressing the level of Fli-1 message [4]. Much of the work in the field of epigenetics, that is non-
DNA-encoded, modifications to the genome has focussed on how patterns of histone modification, 
DNA methylation and chromatin conformation affect the transition between accessible and 
inaccessible gene states and this, in turn, is important to cell differentiation. Heritable epigenetic 
marks are probably essential to the stepwise progression of differentiation and as a cellular memory 
to fix a particular pattern of gene expression. The social environment a cell resides in, particularly the 
exposure of HSCs to haematopoietic cytokines (see below), may establish epigenetic programs that 
are long-term [5] and therefore the interplay between the epigenome and external influences is 
probably crucial to cell decision-making and the progression of cell differentiation. To add to the 
diverse nature of controls, a change to the three-dimensional organisation of the nucleus as a whole 
influences the capacity for cell differentiation towards a specialised cell type [6]. 
2. The Nature of Haematopoietic Stem Cells 
Investigators used various means to show that just one HSC is sufficient to engraft the entire 
haematopoietic system long-term into a recipient irradiated mouse. They included flow cytometry to 
purify HSCs, retroviral tagging of HSCs and suitable immune deficient recipient mice [7]. Notta and 
colleagues cell sorted CD49f+ve cells from cord blood HSCs and optimised the engraftment of single 
cells into a NOD-scid-IL2Rgc−/− (NSG) mouse by using intra-femoral injection. In one experiment, 
they observed multi-lineage chimerism in 5 of 18 mice (28%) and a lower frequency of transfer in the 
second experiment (14%) [8]. The observed frequency of multi-lineage chimerism is rather low and 
relates to either the inefficiency of xenotransplantation [9] or the heterogeneous nature of the HSCs 
purified (see below). Nevertheless, the above study showed that all of the lineage fates are open to 
HSCs at one time during their lifespan. 
The cardinal properties of HSCs derived from transplantation studies are that they are 
pluripotent and self-renew. Since the 1980s, we have viewed HSCs as giving rise to the different blood 
and immune cells by means of HSCs that have selected to differentiate progressing stepwise via a 
series of binary decisions, and intermediate progenitor cells, towards an end cell type. This viewpoint 
has unpinned many of the tree-like lineage maps for haematopoiesis, for example, the “classic” 
lymphoid/myeloid dichotomy map [10]. 
Contrary to the longstanding properties of HSCs, investigators have argued that self-renewal, 
as revealed by transplantation experiments, is not solely a feature of HSCs nor a feature that occurs 
naturally in these cells [11]. Moreover, there is initiation of affiliation to a single cell lineage as early 
as within HSC. Indeed, adult human HSCs are a mixture of some pluripotent cells and many cells 
with lineage-affiliated gene expression signatures [12]. Similarly, mouse HSCs selectively express the 
receptors for cytokines that are lineage-affiliated regarding their role in ensuring the survival and cell 
proliferation of cells that belong to a cell lineage. The receptors include those for erythropoietin (Epo), 
macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating factor (G-CSF), 
granulocyte/macrophage colony-stimulating factor (GM-CSF) and the fms-like tyrosine kinase 3 
ligand (Flt3L) [13]. This individual expression of receptors is highly germane to decision-making 
because the cytokines can instruct the lineage choice of mouse haematopoietic stem and progenitor 
cells (HSPCs). M-CSF instructs myeloid fate in HSCs and macrophage fate in 
granulocyte/macrophage progenitors. G-CSF and GM-CSF provoke the generation of neutrophils 
from granulocyte/macrophage progenitors. Flt3L drives myeloid-lymphoid development of 
primitive mouse bone marrow cells, and suppresses the development of megakaryocyte and 
erythroid progenitors (reviewed in [14]). 
In keeping with many new findings about the architecture of haematopoiesis, our view is that 
HSCs can directly choose one option from the entire spectrum of haematopoietic cell fates (Figure 1). 
Analysis of the transcriptomes of single haematopoietic progenitor cells (HPCs) as they differentiate 
placed the priming of fate potentials on a continuous transcriptional landscape with fate choice 
occurring earlier than previously thought [15]. We have placed particular cell lineages adjacent to 
one another in our continuum model, and evidence to support close relationships is described 
elsewhere [2]. For HSCs and HPCs that have selected a cell lineage, the other options remain 
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latent/clandestine. In other words, they can still change their mind and “choose” an alternative 
developmental pathway (see below) 
 
Figure 1. A continuum model of haematopoiesis. Haematopoietic stem cells (HSCs) “choose” a 
lineage from all options and are a mixture of cells with different lineage signatures (shown by the 
different colours). They and their progeny retain enough versatility to “step sideways” into a different 
pathway. Erythropoietin (Epo), granulocyte colony-stimulating factor (G-
CSF)/granulocyte/macrophage colony-stimulating factor (GM-CSF), and macrophage colony 
stimulating factor (M-CSF), respectively, instruct erythroid, neutrophil, and monocyte fates within 
HSCs/haematopoietic progenitor cells. 
How might HSCs veer towards one versus another pathway? Halley and colleagues have 
argued that stochastic gene expression within the stem cell gene-regulatory network self-organises 
to a critical state leading to a cascade of expression to prime a fate [1]. Similarly, Hu and colleagues 
argued from early studies that examined single multipotent HSPCs, by RT-PCR, for the expression 
of lineage-affiliated genes that there is stochastic and low level “priming” of different lineage 
programs. They observed a “promiscuous” co-expression of cytokine receptor by single cells [16]. It 
is therefore interesting to speculate that cytokine receptor expression may be highly dynamic, based 
on fluctuating gene expression, and play a stochastic role in the precipitation of lineage affiliation. 
Intriguingly, the receptors for the instructive cytokines are positively auto-regulated by cytokine 
engagement. In this scenario, enforcement of a cell lineage affiliation is likely to occur once an HSC 
expresses the receptor and if the cytokine is available in the environment [14]. HSCs express the 
receptor for stem cell factor, to ensure their survival, and the “promiscuous” co-expression of a 
lineage-affiliated cytokine receptor may sound-out developmental options, to comply with the 
demand for a cell type, or provide a survival advantage if there is competition for stem cell factor for 
survival/cell expansion. 
3. Crossing Barriers and “Stepping Sideways” to an Alternative Pathway 
The intracellular barriers that separate highly distinct cell lineages/fate options are surmountable 
as to the four Yamanaka transcription factors Oct4/Sox2/Klf4/c-Myc reprogram somatic cells such as 
adult fibroblasts to induced pluripotent stem (iPS) cells [17]. OCT4 alone is sufficient to reprogram 
mouse neural stem cells to iPS cells [18]. Intrinsic reversibility is perhaps a little contrary to models 
for haematopoiesis that dictated that HSCs invariably develop along inflexible and the shortest routes 
to each end cell fate. However, and as above, alternative fates remain clandestine within HSPCs that 
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have “chosen” a lineage and single-cell RNA sequencing of more than 1600 HSPCs provided insight 
to the availability of options as HSPCs differentiate. Nestorowa and colleagues used single-cell 
expression data to construct differentiation trajectories, leading to the conclusions that they are broad 
and, at any moment in time, cells do have the option of making a sideways movement rather than 
taking the shortest route to an end cell type [19]. In support of broad trajectories is that platelet 
production shares a pathway with the erythroid lineage, and at early stages with the pathways for 
mast cells, eosinophils and basophils [20]. 
Velten and colleagues constructed developmental trajectories by integrating single-cell RNA 
sequencing data with data from single cell cultures that revealed lineage potentials. The data support 
a continuum-based model of early haematopoiesis whereby HSCs gradually acquire lineage biases 
and commitment is a continuous process with barriers that separate lineages deepening gradually. 
Velten and colleagues brought to attention that small differences in developing cells in the expression 
of fate mediators might lead to the initiation of the barriers, favouring an early emergence of lineage-
affiliation and within HSCs [21]. Of further interest is the developmental stage at which barriers are 
insurmountable to the extent that the instructive cytokines are not able to drive developing cells 
towards a fate that is different from the one first chosen (see below). 
Ten percent of murine long-term repopulating HSC (LT-HSCs) express the megakaryocyte-
associated surface antigen CD41 [22] and murine HSCs that express c-Kit at a high level are primed 
to differentiate towards platelets [23]. Around half of murine LT-HSC express the megakaryocyte 
lineage marker von Willebrand Factor (vWF) [24,25] as revealed using a transgenic (vWF)-GFP mouse 
model [26]. Whilst megakaryocyte-affiliated HSCs gave rise to platelet-biased reconstitution of 
irradiated mice, they were not restricted to repopulating platelets. Investigators observed a 
considerable “side-step” contribution to myeloid reconstitution and a low contribution to lymphoid 
reconstitution. As might be expected, biased HSCs are important to “an emergency” whereupon cells 
of a certain lineage are required because there was rapid recruitment of platelet-biased (vWF+ve) 
HSCs to replenish circulating platelets following acute depletion. Megakaryocyte-biased HSCs also 
produced platelets rapidly in the case of acute thrombocytopenia [27]. All of the above supports the 
view that lineage-biased/affiliated cells can give rise to cells of their “chosen” lineage in one 
circumstance and these and other cell types in a different circumstance, for example, an irradiated 
(empty-vessel) mouse. In other words, haematopoiesis is both dynamic and non-linear. 
The barriers to developing haematopoietic cells moving from one lineage choice to another are 
somewhat “fluid” and overcome by lack of just one transcription factor together with treating cells 
with an appropriate cytokine as shown by studies of the B-cell lineage. B-cell lineage cells exclusively 
express the Pax5 gene, encoding the transcription factor B-cell-specific activator protein (BSAP). Pax5-
deficient (Pax5-/-) pro-B cell lines are not restricted in their lineage fate because they develop in vitro 
towards macrophages, dendritic cells, osteoclasts, granulocytes or natural killer cells when cultured 
with an appropriate cytokine. Culture of Pax5-/- pro-B cells on ST2 cells, which produce M-CSF, or 
with M-CSF (without stromal support and after culturing for 10-14 days on ST2 cells) led to 
macrophage differentiation. Terminal differentiation towards dendritic cells required GM-CSF 
instead of M-CSF. The cytokine TRANCE (also known as RANKL) controls the differentiation of 
osteoclasts and culture of the Pax5-/- pro-B cells on ST2 cells that ectopically expressed TRANCE gave 
rise to dendritic cells. Granulocyte differentiation required the presence of IL-6 and G-CSF and a 
small percentage of the cells differentiated, and ILC development required IL-2 and culture with 
stromal cells. Following reconstitution in mice, Pax5-/- pro-B cells gave rise to T cells. Restoration of 
Pax5 activity repressed this lineage versatility and therefore Pax5 plays a role to suppress alternative 
lineage choices in addition to facilitating B-cell development [28,29]. 
More mature progenitors are versatile. Double negative (DN2) thymocytes in the thymus are 
well on their way to becoming T cells but they can still give rise to macrophages, dendritic cells, B-
cells and ILCs (Figure 2) [30–32]. Appropriate culture conditions are crucial to forcing DN1 and DN2 
cells to step sideways. Culture of these cells on ST-2 stromal cells led to the generation of functional 
macrophages [31] and ST-2 cells produce a low level of macrophage colony-stimulating factor (M-
CSF), which can instruct macrophage fate. Macrophage colonies did not arise from DN1 and DN2 
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cells when they were cultured on the M-CSF-non-secreting OP9 stromal cells. Culture of DN1 and 
DN2 cells in the presence of IL-7 and IL-2 led to the generation of ILCs, though IL-7 was not required 
to any large degree. IL-4 and IL-13 guide early thymocyte progenitors to develop towards dendritic 
cells with a CD8α+ve phenotype [32]. 
 
Figure 2. The availability of alternative pathways to developing thymocytes. Thymocytes that are 
well on their way to becoming T cells in the thymus can still give rise to macrophages, dendritic cells 
(DC), B cells and innate lymphoid cells (ILC). Macrophage colony-stimulating factor is required for 
the generation of macrophages. Culture of DN1 and DN2 cells in the presence of IL-7 and IL-2 led to 
the generation of ILC. IL-4 and IL-13 guide early thymocyte progenitors to develop towards DCs. 
During their lifespan, some mature immune cells change the characteristics that affiliate them to 
a sub-type of cells. The different types of the mature CD4+ve effector include T helper 1 cells, T helper 
2 cells (Th2), interleukin (IL) 17-producing T helper cells (Th17), follicular T helper cells (Tfh) and 
regulatory T cells (iTreg). Their sub-type functionality relates to each producing a different array of 
cytokines, for example, Th2 cells produce IL-4, IL-5, IL-13, IL-10 and IL-25 whereas iTreg produce IL-
10, IL-35 and TGFβ. CD4+ve cells can switch from one to another type of CD4+ve cell and 
environmental signals drive the adoption of a new phenotype. Th2 cells can give rise to Tfh cells [33] 
and iTreg can convert to pro-inflammatory Th17 [34]. Memory Th2 cells convert to iTreg when treated 
in vitro with TGF-β and in response to blockade of IFN-γ and IL-4 signalling [35]. Investigators have 
developed mathematical models that predict how the additive integration of signals to T cells from 
cytokines determine the fate outcome of CD4+ve T cells [36]. ILCs are first line against pathogens and 
environmental influences drive a change from one phenotype to another. For example, Group 2 ILCs 
residing in the lungs of mice become group 1 ILCs upon infection by influenza virus and 
Staphylococcus aureus and exposure to cigarette smoke [37]. 
From all of the above, cells are much more versatile/plastic than we previously imagined. 
Developing HSPCs can change their first-choice pathway to a different pathway and the phenotype 
of at least some of the mature immune cells is flexible throughout their lifespan. Perhaps the extent 
that investigators rigorously defined cell surface phenotypes and other functional attributes misled 
us to view acquired characteristics as somewhat fixed. By contrast and as early as 1987, Shankland 
commented that it would be very surprising if cells progressing along a lineage pathway were not 
able to follow a different pathway in response to a particular circumstance. Shankland observed that 
neurons and epidermal specialisations normally descend in the embryo of the leech from the p blast 
cell and that ablation of the P cell line led to neurons and epidermal specialisations arising from a 
different precursor—the o blast cell [38]. In this case, the o blast cell adopts an alternative cell lineage. 
It would be challenging to investigators to chronicle the extent that developing murine HSCPs can 
step sideways in vivo because of the need to ablate, for example, just one population of lineage 
affiliated HSPCs. The identification of these cells has blurred the demarcation between HSCs and 
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HPCs and we might argue that the range of cell types seen in the various colonies arising from single 
HPCs dispersed in semi-solid medium reflects an intrinsic capacity to shuffle sideways. In keeping 
with the continuum model, the founder cells divert to lineages that are adjacent to one another rather 
than in a random manner. 
Haematopoietic stem cells, progenitor cells and end cells moving from one cell lineage/sub-type 
to another appears to involve “switches” that integrate genetic and environmental influences on a 
cell’s phenotype. As to the role of environment influences, the versatility may be adaptive to meet 
the demands of an organism for a particular type of cell. Additionally, central to evolutionary biology 
is explaining how novel traits/cell types arise [39]. The inherent versatility of cells and the extent that 
environmental conditions can guide a cell towards an alternative developmental pathway might 
underlie the evolution of new patterns of traits/cell types. 
4. The Bulk of Leukaemia Cells belong to just One Cell Lineage 
A feature of the bulk of leukaemia and cancer cells is that they resemble just one normal cell type 
and we categorise the various leukaemias, and other cancers, by this means. However, most, if not 
all, leukaemia and other cancers arise from a tissue specific stem cell [40]. Chronic myeloid leukaemia 
(CML) and acute erythroid leukaemia both arise from a haematopoietic stem cell, but strikingly the 
leukaemia cells belong to the neutrophil and erythroid pathways respectively (reviewed in [41]). We 
know quite a lot about many cancers, in particular the oncogenic insults to normal cells leading to 
disease. A question that has received much less attention is how cells are “dumped” down one 
developmental pathway by HSCs in the case of CML and acute erythroid leukaemia. To put this 
question another way: Regarding the many leukaemias and cancers that arise in a tissue-specific stem 
cell, why is the hierarchy of the partially or fully differentiated malignant cells generated not a 
mixture of cell types? 
Investigators and clinicians view childhood B-cell precursor acute lymphoblastic leukaemia (B-
ALL) as arising in a committed B-lineage cell [42]. However, HSC-like cells expressing the stem cell 
marker CD34 and lacking B-lineage markers recreate the disease in mice indicating a primitive cell 
origin for some types of B-ALL [43]. Infant B-ALL (iB-ALL), at <1 year of age, is a different disease 
with a more aggressive presentation and remains fatal as compared to a current 5-year survival 
approaching 90% for childhood B-ALL. Comparison of the gene expression signature of iB-ALL blasts 
with those of human foetal live HSPC populations showed that that the iB-ALL blasts resemble the 
most immature foetal liver HSPCs, similar to that of Lin-ve CD34+ve CD38-ve CD19-ve foetal HSPCs as 
opposed to the distinct signature of foetal liver B-cell committed progenitors. These findings suggest 
that iB-ALL arises in a primitive foetal liver HSPC that is developmentally prior to the “pre-VDJ” 
stage of B-cell development [44]. 
For other leukaemias, findings support an origin in HSCs rather than the long-held viewpoints 
of a lineage-affiliated cell. The genetic alterations for T cell lymphoma [45], follicular lymphoma 
[46,47] and hairy cell leukaemia [48] trace back to the HSC stage of development. Investigators 
categorise acute promyelocytic leukaemia as a myeloid progenitor malignancy [49]. By contrast, the 
fusion PML-RARα oncoprotein, arising from the t(15,17) translocation, is characteristic of acute 
promyelocytic leukaemia and both markers are present in CD34+ve CD38-ve HSC-like cells from 
patients [50]. A customary view is that chronic lymphocytic leukaemia (CLL) is a disease of B-
lymphocytes, but patients’ HSCs that express lymphoid genes indicate that a self-renewing HSC is 
the primary target cell in the pathogenesis of CLL. Additionally, HSCs from patients with CLL 
produce a high number of polyclonal B-cell progenitors [51,52] 
5. Oncogenic Programming of Stem and Progenitor Cells to a Single Cell Lineage 
The LMO2 gene encodes the LIM-only transcription factor (Lmo2) that also has a role in 
promoting DNA synthesis and progression from the G1 phase to S phase of the cell cycle in 
haematopoietic cells [53]. There is often activation of transcription factors in leukaemias and LMO2 
is a target of activation via chromosomal translocations. Strikingly the chromosomal translocations 
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that activate the LMO2 gene occur only in T-cell leukaemias. In other words, the LMO2 gene when 
abnormally expressed exclusively drives T-cell malignancies [54]. 
Despite the T-cell exclusivity of the oncogenic nature of LMO2, McCormack and colleagues have 
argued from conditional knockout of expression of mouse LMO2 that Lmo2 does not have a 
mandatory role in normal T cell development [55]. They expressed the Cre recombinase under the 
control of the promoters of the lymphoid-specific genes Rag1, CD19, and Lck to delete the expression 
of LMO2 in specific cell types. The deletion of Lmo2 was efficient within bone marrow progenitors of 
lymphocytes and there was no disturbance to either T- or B-cell development. However, Lmo2 is 
necessary for early stages of haematopoiesis because homozygous mutant LMO2-/- mouse embryonic 
stem cells do not contribute to haematopoiesis in adult chimeric mice [56]. Lmo2 plays a role in red 
cell development in the embryo yolk sac (primitive erythropoiesis) and might have a role in adult 
haematopoiesis at a stage of development that is earlier than lymphoid progenitors, and in HSPCs 
that is of interest as follows. 
 
Figure 3. Expression of LMO2, BCR-ABLp190 and BCR-ABLp210 leads to T-cell, B-cell and myeloid 
leukaemia respectively. Targeted expression of LMO2 to haematopoietic stem and progenitor cells 
(HSPC) was via Sc1-LMO2. Expression at the pro-B cell stage of development was via crossing Rosa26-
Lmo2 and Mb1 mice to delete the stop cassette at the pro-B-cell level (see main text). Crossing 
conditional Rosa26-Lmo2 mice with the Aid-Cre strain induced Lmo2 expression in GC cells (see main 
text). These enforced expressions led to T-acute lymphoblastic leukaemia (T-ALL). Targeted 
expression of BCR-ABLp190 and BCR-ABLp210 to HSPC, via Sc1-LMO2, led to pre-B acute 
lymphoblastic leukaemia and chronic myeloid leukaemia respectively. 
For human leukaemias, it is difficult to ascertain whether the transforming action of Lmo2 is 
within HSCs or at some later lineage-committed stage of development. This is because there is 
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preservation of the action of Lmo2 that leads to programming of the malignant cell fate in the stem 
cells that maintain the leukaemia, their immediate progeny and the partially differentiated leukaemia 
cells that are the bulk of a patient’s leukaemia cells. The precise role of Lmo2 at each of these different 
developmental stages of the leukaemic cell hierarchy is therefore difficult to unravel by analysing 
patients’ cells. 
To circumvent the caveat to studies of patients’ cells, investigators enforced expression of Lmo2 
in mouse HSPCs and B cells at various stages of their development and only T cell leukaemias arise 
(Figure 3). Targeted and restricted Lmo2 expression in mouse HSCs, by placing LMO2–TdTomato 
cDNA under the control of the stem-cell-specific Sca1 promoter, resulted in a highly disseminated 
human-like T acute lymphoblastic leukaemia (T-ALL), with the resulting leukaemia cells lacking 
expression of Lmo2. To achieve expression of Lmo2 at the pro-B cell stage of development, the 
investigators crossed Rosa26-LMO2 and Mb1 mice to delete the stop cassette at the pro-B-cell level, 
via the Cre recombinase driven by the promoter from the Mb1 locus encoding the immunoglobulin-
associated alpha chain Cd79a. Activation of LMO2 at pro-B cell stage of B-cell development had a 
minimal effect on B-cell development and instead reprogrammed B-cells leading to the development 
of aggressive T-ALL. Crossing conditional Rosa26-LMO2 mice with the Aid-Cre strain, which 
expresses Cre recombinase in germinal center (GC) B cells, led to Lmo2 expression in GC cells. 
Expression of Lmo2 in GC B cells (see Figure 2 legend) did not result in B-cell malignancies and again 
the mice developed aggressive T-ALL. In all the above instances, Lmo2 expression has defined/fixed 
the leukaemia T-cell identity of different target cells and their progeny through reprogramming [57]. 
Two forms of the BCR-ABL oncogene encode the fusion proteins BCR-ABLp190 and BCR-
ABLp210 that are associated with different forms of leukaemia. The BCR-ABLp190 occurs commonly 
in Ph+ve ALL and occasionally in acute myeloid leukaemia. The BCR-ABLp210 occurs in patients 
with CML, and in acute lymphoid and myeloid leukaemias [58]. There are healthy individuals that 
have the CML-associated BCR-ABLp210 transcripts, with reported incidences ranging from 10% to 
30% of adult peripheral blood samples tested (reviewed in [59]). Similarly, investigators have found 
cells that have the BCR-ABLp190 lesion in neonatal cord blood and the majority of carriers did not 
develop B-cell ALL [60,61]. The presence of single BCR-ABLp190 mutation seems to be insufficient to 
cause B-cell ALL, other cooperating mutations are required and the cells that just have the mutation 
are premalignant. 
Gene targeting experiments have addressed the roles of BCR-ABLp190 and BCR-ABLp210 in the 
genesis of leukaemia (Figure 3). Investigators modelled the role of BCR-ABLp190 in mice and 
expression was restricted to HSPC by means of Sca1-BCR-ABLp190. The mice developed B-ALL at a 
low penetrance. The leukaemic blast cells were transcriptionally pro-B/pre-B cells, resembled the 
human disease and did not express BCR-ABLp190. The oncogenic action of BCR-ABLp190 is 
therefore hit-and-run. A short disease latency and 90% incidence was observed for double Sca1-BCR-
ABLp190 + Pax5+/- mice and an accumulation of genomic alterations was observed in in the remaining 
wild-type Pax5 allele. A number of metabolic genes (IDH1, G6PC3, GAPDH, PGK1, MYC, ENO1, 
ACO1) were upregulated in the Pax5-deficient leukemic cells, and human leukeamia cells have a 
similar metabolic signature. This finding led investigators to propose that disease occurs upon 
reduced Pax5 functionality and that metabolic reprogramming combined with Sca-restricted BCR-
ABLp190 expression leads to successful transformation [62]. The Pax5 B-cell specific transcription 
factor is present in pro-B cells and in all further stages of B cell development until the plasma cell 
stage. As to disease requiring reduced Pax5, it therefore seems unlikely that disease occurred in a 
committed Pax5+ve pro-B/pre-B cell that had acquired stem cell-like properties to sustain disease. 
Additionally, and in keeping with the stem cell-origin theory of cancer [40], there is no demonstration 
of an oncogene reverting a committed cell to a stem cell-like state and committed epithelial cells do 
not give rise to the malignant squamous cell carcinomas [63]. An alternative view regarding disease 
initiation is that Sca1-restriction of BCR-ABLp190 expression to HSPCs has “wired” HSPCs that do 
not express Pax5 to a leukaemic phenotype including imposing B-cell lineage development. 
In contrast to BCR-ABLp190, transient expression of BCR-ABLp210 restricted to the HSPC 
compartment of mice led to mature myeloid leukaemia [64,65]. Again, the disease in mice resembles 
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human CML. CML stem cells are not dependent on the BCR-ABLp210 tyrosine kinase activity 
because the clinical use of ABL kinase inhibitors does not cure the disease. The disease returns upon 
cessation of treatment due to the persistence of CML stem cells or the development of resistance [66]. 
As to the persistence of disease following kinase inhibition, an oncogenic activity of BCR-ABLp210 is 
therefore distinct from the ABL kinase activity and a postulate regarding this additional activity is 
that BCR-ABLp210 instruct myeloid development of the malignant HSC [65]. 
6. How Might Hard Wiring of Leukaemia Stem Cells to One Cell Lineage Occur? 
For HSCs, the oncogene-mediated hard wiring to a cell lineage might occur within HSCs or a 
later stage of affiliation of HSCs to a cell lineage. As outlined above, HSCs are sufficiently versatility 
for the programming to occur. In the case of hard wiring of an offspring of HSCs, the oncogene action 
might synergise with a lineage-affiliate event(s), which is either intrinsic to the cell or driven 
externally. Fixation of a lineage affiliation might occur via wiring of the network of transcriptional 
factors. Alternatively, certain oncogenes might either reshape the epigenome or remodel the 
architecture of chromatin. We favour the view that oncogenic insults to the genome shape the 
epigenome [57]. 
The transcription factor Lmo2 is at the very core of the identity of HSPCs. Lmo2 is required for 
TAL1 to bind to DNA and this is important at the haemangioblast stage of haematopoiesis to position 
the TAL1/Lmo2/LDB1 complex to regulatory elements to establish the developmental program and 
initiate definitive haematopoiesis [67]. In keeping is that in chimeric mice Lmo2-/- cells do not 
contribute to definitive haematopoiesis [68]. Even so, it is important to separate the function of Lmo2 
in the haemangioblast to establish haematopoiesis and a role in the T-ALL arising from the enforced 
oncogene expression. A possibility is that oncogene enforced Lmo2 expression within HSCs leads to 
over-expression that persists when these cells become T-cell lineage affiliated. In this case, the 
abnormal expression of Lmo2 together with transcription factors that play an obligatory role during 
T-cell development, for example E2A-Heb heterodimers [69], may be important, and Lmo2 endows 
stem cell attributes as to driving self-renewal of thymocytes [70]. 
 
Figure 4. Links between Lmo2, epigenetic regulation and Il-2 gene expression. Lmo2 recruits Sap18 
and histone deacetylase 1 (HDAC1) to repress transcription of ZEB1 via histone deacetylation at the 
ZEB1 promotor. ZEB1 cooperates with CtBP2 and HDAC1 to repress IL-2 gene expression. 
Whereupon oncogenic Lmo2 represses the transcription of ZEB1 there might be expression of IL-2. 
Lmo2 plays a role in chromatin remodelling. As considered above, some haematopoietic 
cytokines instruct cell lineage and ensure the survival and proliferation of lineage-affiliated cells. 
There is an intriguing link between Lmo2 expression and the epigenetic regulation of the expression 
of the T-cell associated cytokine IL-2 (Figure 4). Oncogenic Lmo2 recruits Sap18 and histone 
deacetylase 1 (HDAC1) and this epigenetic regulatory complex represses transcription of ZEB1, a 
member of the zinc finger-homeodomain family of transcription factors, by means of histone 
deacetylation at the ZEB1 promotor and chromatin remodelling. Epigenetic dysregulation of ZEB1 is 
involved in the genesis of T-ALL and ZEB1 plays a role in normal T-cells by cooperating with CtBP2 
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and HDAC1 to repress the expression of the IL-2 gene [71]. Whereupon oncogenic Lmo2 represses 
the transcription of ZEB1, there might be expression of IL-2 to drive either T-cell expansion or effector 
T-cell differentiation [72]. Suppression of ZEB1 expression also affects signalling by transforming 
growth factor-β1 because ZEB1 has an enhancing role as revealed by ectopic expression. Accordingly, 
ZEB1 is a candidate tumour-suppressor gene and down-regulation contributes to resistance to TGF-
β1-mediated growth suppression in adult T-ALL and lymphoma [73]. Lmo2 and ZEB1 can also 
influence the stem-ness of cells. Overexpression of Lmo2 leading to suppression of ZEB1 expression 
within the leukaemic T cell lines Jurkat and MOLT4 increased the appearance of cells expressing stem 
cell properties (CD117+ve and CD34+ve) and rescue of ZEB1 expression attenuated this effect [74]. 
From all of the above it is important to bear in mind that we should not view Lmo2-provoked 
changes to the transcription factor network and the epigenome as separable. Additionally, 
consideration of Lmo2-provoked changes to the levels of and signalling by haematopoietic cytokines 
are important because such is crucial to the normal conduct of haematopoiesis. There are intriguing 
links between Lmo2 expression and changes to the transcription factor network, the epigenetic status 
of cells and the levels/actions of cytokines. Presently, we do not know how events might conspire to 
“fix” HSCs and their progeny to the T-cell lineage, if this is the case, and lead to overt leukaemia. 
When pieces of chromosomes 9 and 22 change places to give rise to the shorter Ph 22 
chromosome, the ABL gene (on chromosome 9) joins to the BCR gene (on chromosome 22) to form 
the BCR-ABL fusion gene. The encoded hybrid protein is a constitutively active tyrosine kinase and 
this is important as clinicians use tyrosine kinase inhibitors to treat CML successfully. So far, it is hard 
to see how the two forms of BCR-ABL forms clearly associate with different leukaemias and there are 
two possibilities. One is that the intrinsic leukaemogenic activity within the cell that has the 
translocation, and is expressing BCR-ABL, is different for the two forms. Alternatively, the activity 
of the two forms is the same and the expression of each form is somehow restricted to different 
haematopoietic cell lineages because a given lineage favours a particular breakpoint during the 
formation of the Ph chromosome. 
A hypothesis is that BCR-ABLp210 “wires” the transformed HSC and its progeny cells to the 
myeloid differentiation pathway by fuelling epigenetic changes. Reduced representation bisulfite 
sequencing to interrogate the DNA methylation landscape in HSPCs (Sca1+ve Lin−ve) from wild type 
and Sca1-BCR-ABLp210 transgenic mice revealed global hypomethylation within the HSPCs from 
the Sca1-BCR-ABLp210 mice, and in the mature myeloid cells despite their lack of expression of BCR-
ABLp210 [65]. The broad loss of methylation was at CpG islands. Investigators have shown that there 
is over expression of DNA methyltransferas (DNMT) genes, including DNMT1, in myeloid 
leukemias [75]. Within HSPCs from the Sca1-BCR-ABLp210 mice, as compared to wild type mice, 
Dntm1 gene expression was upregulated, Dmt3b downregulated and there was no change in Dnmt3a 
[65]. The finding that Sca1-Dnmt1 mice develop myeloid malignancies with marked expansion of 
granulocytes in the blood and bone marrow supports Dntm1 expression playing an important role in 
CML. All of the above provides support to the notion that BCR-ABLp210-provoked changes to the 
epigenome “fix” the lineage identity of the transformed HSC and its progeny leukaemia cells to that 
of myeloid development [reviewed in 65]. 
7. Concluding Remarks 
The arguments presented above centre around the extent normal and leukaemia stem cells and 
their progeny can cross the “boundaries” that delineate one cell lineage from another as cells develop 
along a pathway. We have argued that this is different for HSCs and leukaemia stem cells (LSCs) and 
their progeny whereby LSCs and their progeny do not have the capacity to follow an alternative 
pathway after they have affiliated to a cell lineage. There is good evidence to support the view that 
normal HSCs and their progeny are indeed versatile and experimental evidence to support oncogene 
priming of the epigenome of leukaemia cells such that they adopt one cell lineage. The pathological 
cell identity established is specific for each different oncogene. We believe that hard wiring of 
transformed cells to a cell lineage is a characteristic of many cancers because stem cells are largely the 
origin of “successful” cancers. The instructive cytokines provide a unique opportunity to test whether 
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leukaemia cells are hard-wired which is important to the way we treat cancer. We can erase epigenetic 
insults to the genome and indeed the HDAC inhibitors vorinostat, romidepsin and belinostat have 
approval for treating some T-cell lymphoma patients and panobinostat for treating multiple 
myeloma patients. Other inhibitors are in clinical trial for the treatment of leukaemias and solid 
cancers. These agents have what seems a bright future as one of the tools to fight against cancer. 
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